Supplement Industry Warnings Near 2016 Total Midway Through 2017
This article was originally published in The Rose Sheet
Executive Summary
FDA warning letters to herbal supplement firms in Alabama and New York add to the agency's list of supplement marketers making drug claims for their products, including statements suggesting products could address cancer, sexual health and heart and prostate issues.
You may also be interested in...
Dietary Supplement Sector Warnings Jump With FDA 'Program Alignment'
Some stakeholders complained FDA inspectors unfamiliar with Part 111 inappropriately held supplement firms to drug or food product manufacturing regulations, but the agency's assignment of inspectors with greater expertise on the regulations could be turning up compliance problems in the sector that other ORA officials might have missed.
Regulatory Problems Mount For Supplement Firm Following Recall
in addition to distributing supplements containing ED ingredients, MS Bionic was in violation of an extensive list of supplement GMP regulations. Meanwhile Absonutrix makes claims for its herbals and botanicals including "aids in the inhibition of colon cancer cell growth and survival."
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.